C3球球症患者の経口イプタコパンの治療:ランダム化,ダブルブラインド,並列群,多センター,プラセボ対照,第3相試験
David Kavanagh1, Andrew S Bomback2, Marina Vivarelli3
1Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Lancet (London, England)
|September 28, 2025
まとめ
イプタコパンは,代替補完経路を阻害することで,C3型グルメロパシー患者のタンパク質尿を有意に減少させた. この経口治療は,第3相臨床試験で好ましい安全性プロファイルを示した.
科学分野:
- 腎臓科
- 免疫学
- 薬理学について
背景:
- C3グルメロパシー (C3G) は,代替補足経路の過剰活性化によって引き起こされる希少で重症な腎疾患です.
- 代替補充経路をターゲットにすることで,C3Gの潜在的な治療戦略が提供されます.
- イプタコパンは,選択的にファクターBを標的とする口服付近補完剤です.
研究 の 目的:
- バイオプシーで確認されたC3球球症の成人の患者におけるイプタコパンの有効性と安全性の評価.
- 標準治療と併用してイプタコパンを投与する患者におけるタンパク質尿の減少を評価する.
主な方法:
- 多中心,ランダム化,ダブルブラインド,プラセボ対照の第3相研究 (APPEAR- C3G) には74人の成人C3G患者が参加した.
- 参加者はイプタコパンまたはプラセボと6ヶ月間サポートケア (RAAS阻害剤) と免疫抑制を受けた.
- 主なエンドポイントは,尿中の24時間タンパク質- クレアチニン比率 (UPCR) の相対的な低下でした.
主要な成果:
- イプタコパンは,プラセボと比較して6ヶ月で統計的に有意な相対的なUPCRの減少を示した (p=0. 0014).
- プラセボ群では2. 58g/ gから2. 80g/ gに増加した.
- イプタコパンはよく耐えており,有害事象は主に軽度から中等度であったが,有害事象による死亡や治療中止は発生しなかった.
結論:
- イプタコパンはC3G患者のタンパク質尿を統計的に有意かつ臨床的に有意に減少させる.
- 経口補充剤のイプタコパンは,この患者群で許容可能な安全性プロファイルを示しています.
- イプタコパンはC3球球症の治療に有望な治療法である.
関連する概念動画
Blind Procedures
10.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.8K
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Blinding
2.9K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Peripheral Artery Disease III: Interprofessional Care
655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
434
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
434


